Kyprolis

(carfilzomib)

ApprovedSmall molecule

Carfilzomib is used to treat multiple myeloma, a cancer of plasma cells in the bone marrow. It works by blocking proteins that help cancer cells survive and grow.[2] Kyprolis is currently approved and in use across 28 indications[4].[1]

Kyprolis is one of 334 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Approved.

Indications

212

Total Trials

Active Trials

333

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Neuroendocrine CarcinomaApproved

Kidney CancerApproved

LeukemiaApproved

Unspecified Peripheral T-Cell LymphomaApproved

Prolymphocytic LeukemiaApproved

Recurrent Multiple MyelomaRecruiting

Newly Diagnosed Multiple MyelomaNot yet recruiting

Recurrent Plasma Cell MyelomaActive, not recruiting

Relapsed/refractory Multiple MyelomaRecruiting

Colorectal NeoplasmsNot yet recruiting

Neuroendocrine CarcinomaApproved

Approved

Kidney CancerApproved

Approved

LeukemiaApproved

Approved

Unspecified Peripheral T-Cell LymphomaApproved

Approved

Prolymphocytic LeukemiaApproved

Approved

Recurrent Multiple MyelomaPhase 1

Recruiting

Newly Diagnosed Multiple MyelomaApproved

Not yet recruiting

Recurrent Plasma Cell MyelomaPhase 2

Active, not recruiting

Relapsed/refractory Multiple MyelomaPreclinical

Recruiting

Colorectal NeoplasmsPhase 1

Not yet recruiting

Showing 10 of 28 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Kyprolis

VVirionyx Corporation Limited

Approved

1 2

Tabrecta

Novartis

Phase 3

8 3

Rozlytrek

Roche

Phase 3

4 4

Retevmo

Eli Lilly

Phase 3

4 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

MRD

NCT05434689

Phase 2Active, not recruiting

Multiple Myeloma

NCT04925193

Phase 2Active, not recruiting

Carfilzomib

NCT03314636

PreclinicalRecruiting

Relapsed/refractory Multiple Myeloma

NCT04973605

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT03989414

N/ARecruiting

Multiple Myeloma

NCT06793475

Clinical

Trials by Indication[1]

Multiple Myeloma120 trials

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Unknown status·—··NCT05495620·300 enrolled

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02095834·18 enrolled

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Terminated· Novartis logo

Novartis·Phase 1·NCT02235740·1 enrolled

Show 117 more trials

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04925193·18 enrolled

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT06409702·59 enrolled

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01998971·240 enrolled

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Active, not recruiting·UUniversity of Chicago·Phase 3·NCT02659293·180 enrolled

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01246063·40 enrolled

Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

Recruiting·TThe First Affiliated Hospital of Soochow University··NCT06682156·50 enrolled

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT03605719·23 enrolled

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT01863550·1,087 enrolled

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1·NCT02335983·107 enrolled

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Active, not recruiting·MMayo Clinic·Phase 2·NCT05497804·17 enrolled

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Completed·AAjai Chari·Phase 2·NCT01775553·13 enrolled

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Suspended·HHackensack Meridian Health·Phase 2·NCT04661137·96 enrolled

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 1·NCT01537861·7 enrolled

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Terminated· Teva logo

Teva·Phase 1·NCT05556616·15 enrolled

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·—·Phase 2·NCT05896228·30 enrolled

A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01302392·315 enrolled

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Chicago·Phase 1/2·NCT01665794·25 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01572480·55 enrolled

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06232707

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Terminated· Pfizer logo

Pfizer·Phase 1·NCT03530683·189 enrolled

Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Completed·UUniversity Hospital, Lille·Phase 2·NCT02302495·32 enrolled

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01351623·44 enrolled

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Completed·UUniversity of Chicago·Phase 2·NCT02969837·46 enrolled

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

Completed· Amgen logo

Amgen·Phase 1/2·NCT00531284·184 enrolled

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Completed·EEuropean Myeloma Network B.V.·Phase 1/2·NCT02185820·57 enrolled

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Completed· Takeda logo

Takeda·Phase 4·NCT03416374·45 enrolled

Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma

Terminated·EEmory University·Phase 2·NCT01969565·1 enrolled

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03031730·35 enrolled

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT01980589·22 enrolled

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Active, not recruiting·PPETHEMA Foundation·Phase 3·NCT03742297·462 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Active, not recruiting·UUniversity of Chicago·Phase 3·NCT03729804·250 enrolled

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Completed· Sanofi logo

Sanofi·Phase 3·NCT03275285·302 enrolled

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05572515·614 enrolled

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03290950·75 enrolled

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Enrolling by invitation·LLandspitali University Hospital·Phase 2·NCT03815279·80 enrolled

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Completed· Amgen logo

Amgen·Phase 3·NCT03158688·466 enrolled

Home Treatment With Carfilzomib in Patients With Multiple Myeloma

Recruiting·TThomas Lund··NCT05620238·12 enrolled

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

Completed· Amgen logo

Amgen·Phase 1·NCT01949532·26 enrolled

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Unknown status·PPETHEMA Foundation·Phase 2·NCT03336073·199 enrolled

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Completed· Roche logo

Roche·Phase 1/2·NCT06055075·19 enrolled

Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06793475·20 enrolled

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03989414·424 enrolled

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT03500445·75 enrolled

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Terminated·UUniversity of Washington·Phase 2·NCT03256045·9 enrolled

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Recruiting·UUniversity of Chicago·Phase 2·NCT05789303·83 enrolled

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Terminated·AAttaya Suvannasankha·Phase 2·NCT02020941·10 enrolled

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT02891811·124 enrolled

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Completed·IiOMEDICO AG··NCT02970747·359 enrolled

Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)

Unknown status·LLoyola University·Phase 1/2·NCT03795597·36 enrolled

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT03859427·454 enrolled

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

Withdrawn·KKaryopharm Therapeutics Inc·Phase 2·NCT02628704

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Miami·Phase 2·NCT04268498·310 enrolled

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn· Novartis logo

Novartis·Phase 2·NCT02756663

Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma

Completed·NNorwegian University of Science and Technology·Phase 1·NCT04163107·19 enrolled

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT03029234·126 enrolled

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT07082270·21 enrolled

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Active, not recruiting·NNantes University Hospital·Phase 2·NCT03606577·50 enrolled

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Terminated· AbbVie logo

AbbVie·Phase 1·NCT04895410·8 enrolled

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT02415413·90 enrolled

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Active, not recruiting·PPoitiers University Hospital·Phase 2·NCT04287855·82 enrolled

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1·NCT00603447·84 enrolled

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

Completed· Amgen logo

Amgen·Phase 3·NCT01568866·929 enrolled

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01301807·63 enrolled

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05704049·118 enrolled

Combination Study for High Risk Multiple Myeloma Patients

Terminated·OOncotherapeutics·Phase 2·NCT03104270·13 enrolled

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Active, not recruiting·MMayo Clinic·Phase 1/2·NCT04764942·39 enrolled

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02773030·466 enrolled

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT01962792·84 enrolled

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Completed·WWake Forest University Health Sciences·Phase 1/2·NCT03773107·12 enrolled

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Completed·SStichting European Myeloma Network·Phase 1/2·NCT02056756·63 enrolled

Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT01549431·32 enrolled

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Recruiting·HHackensack Meridian Health·Phase 1·NCT03909412·18 enrolled

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 2·NCT00511238·312 enrolled

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Approved for marketing· Amgen logo

Amgen··NCT01410500

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Terminated· Amgen logo

Amgen·Phase 2·NCT03512353·7 enrolled

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT01842308·50 enrolled

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03412565·265 enrolled

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Completed· Amgen logo

Amgen·Phase 2·NCT00721734·50 enrolled

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 1/2·NCT01677858·116 enrolled

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01080391·792 enrolled

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Terminated·CCriterium, Inc.·Phase 1/2·NCT01464034·136 enrolled

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Terminated·—·Phase 1/2·NCT02002598·23 enrolled

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Active, not recruiting·EEmory University·Phase 2·NCT03756896·29 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01402284·45 enrolled

Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Completed·EEuropean Myeloma Network B.V.·Phase 1/2·NCT02204241·36 enrolled

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02597062·76 enrolled

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT02412878·478 enrolled

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Chicago·Phase 1·NCT02199665·52 enrolled

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Terminated·OOncotherapeutics·Phase 2·NCT02294357·45 enrolled

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Withdrawn·MMayo Clinic·Phase 2·NCT01812720

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Terminated· Gilead logo

Gilead·Phase 2·NCT04892446·36 enrolled

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Completed·EEuropean Myeloma Network B.V.·Phase 1/2·NCT01857115·63 enrolled

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT01057225·64 enrolled

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT01496118·80 enrolled

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02802163

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02101944·12 enrolled

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01818752·955 enrolled

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT06356571·64 enrolled

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 2·NCT00530816·164 enrolled

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05552976·525 enrolled

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting·TThomas Martin, MD·Phase 1·NCT02332850·83 enrolled

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT02899052·120 enrolled

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Active, not recruiting·MMario Boccadoro·Phase 2·NCT02203643·477 enrolled

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02036502·77 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT01816971·76 enrolled

A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04933539·14 enrolled

2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Recruiting· Roche logo

Roche·Phase 3·NCT07555938·380 enrolled

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07391657·508 enrolled

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05050097·166 enrolled

A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05438043·213 enrolled

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT06158841·421 enrolled

A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)

Recruiting· GSK logo

GSK·Phase 2·NCT07227311·200 enrolled

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06152575·492 enrolled

A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma

Completed·WWeill Medical College of Cornell University·Phase 2·NCT01559935·74 enrolled

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT05675449·59 enrolled

Dexamethasone6 trials

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

Not yet recruiting·—·Phase 2·NCT05909826·49 enrolled

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT03673826·58 enrolled

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Recruiting·—·Phase 2·NCT04176718·43 enrolled

Show 3 more trials

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

Unknown status·SSamsung Medical Center·Phase 2·NCT05509374·33 enrolled

Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients

Completed·TTel-Aviv Sourasky Medical Center·Phase 2·NCT04065789·41 enrolled

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Active, not recruiting·WWuerzburg University Hospital·Phase 3·NCT03948035·576 enrolled

Lymphoma5 trials

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Terminated·—·Phase 1/2·NCT02867618·14 enrolled

Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients

Completed·UUniversity of Birmingham·Phase 1/2·NCT03141203·50 enrolled

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02341014·27 enrolled

Show 2 more trials

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Completed·UUniversity of Nebraska·Phase 1·NCT01336920·15 enrolled

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·UUniversity of California, San Francisco·Phase 1·NCT02187133·10 enrolled

Carfilzomib4 trials

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Completed·SStanford University·Phase 1·NCT02512926·4 enrolled

UARK 2009-32 Compassionate Use Study of Carfilzomib

No longer available·UUniversity of Arkansas··NCT00999414

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

Completed· Amgen logo

Amgen·Phase 2·NCT00884312·101 enrolled

Show 1 more trial

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Active, not recruiting·OOslo University Hospital·Phase 2·NCT03314636·53 enrolled

Recurrent Multiple Myeloma4 trials

Isa-CAPED MM: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple Myeloma

Active, not recruiting·UUniversity of Washington·Phase 2·NCT04883242·30 enrolled

A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06948084·80 enrolled

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06622005·15 enrolled

Show 1 more trial

Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07463807·162 enrolled

46 more indications

Desensitization3 trials

Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization

Withdrawn·—·Phase 2·NCT03805178

Carfilzomib and Belatacept for Desensitization

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05017545·21 enrolled

B-Cell Targeted Carfilzomib Desensitization

Unknown status·EE. Steve Woodle·Phase 1·NCT02442648·32 enrolled

Newly Diagnosed3 trials

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

Completed·CCriterium, Inc.·Phase 1·NCT01660750·29 enrolled

High Dose Carfilzomib for Newly Diagnosed Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02937571·29 enrolled

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

Active, not recruiting·FFondazione EMN Italy Onlus·Phase 3·NCT04096066·84 enrolled

Mantle Cell Lymphoma3 trials

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02269085·8 enrolled

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01729104·18 enrolled

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02042950·6 enrolled

Acute Lymphoblastic Leukemia3 trials

Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia

Completed·WWashington University School of Medicine·Phase 1·NCT01137747·18 enrolled

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed· Amgen logo

Amgen·Phase 1·NCT02303821·141 enrolled

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Completed·MMehrdad Abedi, MD·Phase 1·NCT02293109·10 enrolled

Lenalidomide2 trials

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

Recruiting·PPETHEMA Foundation·Phase 1/2·NCT05060627·60 enrolled

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Completed· Amgen logo

Amgen·Phase 2·NCT04191616·54 enrolled

Advanced Malignancies2 trials

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02265510·83 enrolled

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Completed· Amgen logo

Amgen·Phase 1·NCT01949545·46 enrolled

Macroglobulinemia2 trials

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT01470196·31 enrolled

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Completed·HHackensack Meridian Health·Phase 2·NCT01813227·7 enrolled

Stem Cell Transplant2 trials

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02114502

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01658904·3 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed·—·Phase 1/2·NCT02073097·48 enrolled

Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01926665·2 enrolled

Hematological Malignancies2 trials

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Completed·TTragara Pharmaceuticals, Inc.·Phase 1·NCT01204164·120 enrolled

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Completed· Amgen logo

Amgen·Phase 1·NCT00150462·48 enrolled

Plasma Cell Leukemia2 trials

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01372540·76 enrolled

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07605416·74 enrolled

Lung Cancer1 trial

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 1/2·NCT01987232·32 enrolled

Hematologic Malignancies1 trial

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02145403·53 enrolled

Relapsed or Refractory1 trial

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT01903811·143 enrolled

Patients With Advanced Solid Tumors1 trial

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

Completed·EEmory University·Phase 1·NCT02257476·22 enrolled

Chronic Graft Versus Host Disease1 trial

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02491359·20 enrolled

Small Cell Lung Cancer1 trial

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Completed·CCancer Research and Biostatistics Clinical Trials Consortium·Phase 1/2·NCT01941316·78 enrolled

Non-Small Cell Lung Cancer1 trial

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting·—·Phase 1·NCT06249282·15 enrolled

Chronic Lymphocytic Leukemia1 trial

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT01212380·21 enrolled

BTK Inhibitors1 trial

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 2·NCT03891355·16 enrolled

Renal Cell Carcinoma1 trial

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01775930·10 enrolled

Maintenance Treatment1 trial

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Active, not recruiting·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2·NCT03104842·246 enrolled

Cutaneous T-cell lymphoma1 trial

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

Terminated·NNorthwestern University·Phase 1·NCT01738594·7 enrolled

Breast Cancer1 trial

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated·MMayo Clinic·Phase 1·NCT03432741·17 enrolled

Relapsed/Refractory1 trial

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Completed·MMassachusetts General Hospital·Phase 1·NCT02142530·19 enrolled

Prostate Cancer1 trial

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02047253·28 enrolled

Hematopoietic Cell Transplantation1 trial

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03556332·41 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT01690143·45 enrolled

AL amyloidosis1 trial

A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis

Completed·UUniversity College, London·Phase 1/2·NCT02545907·10 enrolled

Amyloidosis1 trial

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Completed·CCriterium, Inc.·Phase 1·NCT01789242·32 enrolled

MRD1 trial

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05434689·80 enrolled

Neuroendocrine Cancer1 trial

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02318784·62 enrolled

Waldenstrom macroglobulinemia1 trial

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Terminated·UUniversity of Washington·Phase 2·NCT03269552·4 enrolled

Lung Transplantation1 trial

Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

Completed·—·Phase 2·NCT02474927·22 enrolled

ESS1 trial

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Active, not recruiting·IInternational Myeloma Foundation·Phase 2·NCT03289299·87 enrolled

Colorectal Neoplasms1 trial

Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07715903·20 enrolled

Recurrent Plasma Cell Myeloma1 trial

Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have Received 1 - 3 Prior Lines of Therapy

Active, not recruiting·AAcademic and Community Cancer Research United·Phase 2·NCT04756401·8 enrolled

Relapsed or Refractory Multiple Myeloma (RRMM)1 trial

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06615479·440 enrolled

Myeloma1 trial

Phase I/II Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma.

Completed·NNantes University Hospital·Preclinical·NCT01279694·72 enrolled

Relapsed and/or Refractory Multiple Myeloma1 trial

An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07222761·915 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Recruiting·BBeOne Medicines·Preclinical·NCT04973605·246 enrolled

Relapse Multiple Myeloma1 trial

Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma

Recruiting·NNatalie Callander·Preclinical·NCT07479979·62 enrolled

CD20 Positive1 trial

Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT01959698·29 enrolled

Extramedullary Disease in Multiple Myeloma1 trial

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06627751·28 enrolled

Kidney Transplant Rejection1 trial

Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06918990·25 enrolled

Unspecified1 trial

KRDI in Transplant-Eligible MM

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04430894·50 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 20, 2012

KYPROLIS

NDA NDA202714

Apr 19, 2013

KYPROLIS

NDA NDA202714

Jan 31, 2014

KYPROLIS

NDA NDA202714

Jun 2, 2014

KYPROLIS

NDA NDA202714

Nov 3, 2014

KYPROLIS

NDA NDA202714

Mar 27, 2015

KYPROLIS

NDA NDA202714

Apr 21, 2015

KYPROLIS

NDA NDA202714

Apr 24, 2015

KYPROLIS

NDA NDA202714

Jul 24, 2015

KYPROLIS

NDA NDA202714

Jan 21, 2016

KYPROLIS

NDA NDA202714

May 23, 2016

KYPROLIS

NDA NDA202714

Jun 3, 2016

KYPROLIS

NDA NDA202714

Aug 4, 2016

KYPROLIS

NDA NDA202714

Nov 17, 2016

KYPROLIS

NDA NDA202714

Nov 21, 2016

KYPROLIS

NDA NDA202714

May 25, 2017

KYPROLIS

NDA NDA202714

Jan 17, 2018

KYPROLIS

NDA NDA202714

Jun 7, 2018

KYPROLIS

NDA NDA202714

Jun 7, 2018

KYPROLIS

NDA NDA202714

Sep 28, 2018

KYPROLIS

NDA NDA202714

Feb 28, 2019

KYPROLIS

NDA NDA202714

Oct 4, 2019

KYPROLIS

NDA NDA202714

May 7, 2020

KYPROLIS

NDA NDA202714

Aug 20, 2020

KYPROLIS

NDA NDA202714

Mar 9, 2021

KYPROLIS

NDA NDA202714

Nov 30, 2021

KYPROLIS

NDA NDA202714

Jun 30, 2022

KYPROLIS

NDA NDA202714

May 22, 2025

KYPROLIS

NDA NDA202714

Sources

References

[1]
ClinicalTrials.gov — 212 trial records for carfilzomib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Kyprolis drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — carfilzomib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for carfilzomib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202714). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Kyprolis. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Virionyx Corporation Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: 26s PROTEASOME Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: VVirionyx Corporation Limited

Patent Landscape[6]

Patent Cliff

Jan 20, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7417042Jul 20, 2026

7417042*PEDJan 20, 2027

7737112Dec 7, 2027

7737112*PEDJun 7, 2028

RE47954Oct 21, 2029

4 more patents

RE47954*PEDApr 21, 2030

9493582*PEDAug 27, 2033

12636340Apr 28, 2041

12636340*PEDOct 28, 2041

Kyprolis

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Multiple Myeloma120 trials

Dexamethasone6 trials

Lymphoma5 trials

Carfilzomib4 trials

Recurrent Multiple Myeloma4 trials

Desensitization3 trials

Newly Diagnosed3 trials

Mantle Cell Lymphoma3 trials

Acute Lymphoblastic Leukemia3 trials

Lenalidomide2 trials

Advanced Malignancies2 trials

Macroglobulinemia2 trials

Stem Cell Transplant2 trials

Diffuse Large B-Cell Lymphoma2 trials

Hematological Malignancies2 trials

Plasma Cell Leukemia2 trials

Lung Cancer1 trial

Hematologic Malignancies1 trial

Relapsed or Refractory1 trial

Patients With Advanced Solid Tumors1 trial

Chronic Graft Versus Host Disease1 trial

Small Cell Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

BTK Inhibitors1 trial

Renal Cell Carcinoma1 trial

Maintenance Treatment1 trial

Cutaneous T-cell lymphoma1 trial

Breast Cancer1 trial

Relapsed/Refractory1 trial

Prostate Cancer1 trial

Hematopoietic Cell Transplantation1 trial

Autologous Hematopoietic Stem Cell Transplantation1 trial

AL amyloidosis1 trial

Amyloidosis1 trial

MRD1 trial

Neuroendocrine Cancer1 trial

Waldenstrom macroglobulinemia1 trial

Lung Transplantation1 trial

ESS1 trial

Colorectal Neoplasms1 trial

Recurrent Plasma Cell Myeloma1 trial

Relapsed or Refractory Multiple Myeloma (RRMM)1 trial

Myeloma1 trial

Relapsed and/or Refractory Multiple Myeloma1 trial

Relapsed/Refractory Multiple Myeloma1 trial

Relapse Multiple Myeloma1 trial

CD20 Positive1 trial

Extramedullary Disease in Multiple Myeloma1 trial

Kidney Transplant Rejection1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News